C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S99, 2014 Special supplement with the abstract book of LATINFARMA 2013 Conference C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES Gracia Medina E. Medical Oncology Department. National Institute of Oncology and Radiobiology, La Habana, Cuba. E-mail: oncmedica@inor.sld.cu Abstract Immunotherapy has been used systematically … Continue reading C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES

J Pharm Pharmacogn Res 2(Suppl. 1): S99, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES

Gracia Medina E.

Medical Oncology Department. National Institute of Oncology and Radiobiology, La Habana, Cuba.
Abstract

Immunotherapy has been used systematically for the treatment of non Hodgkin’s Lymphomas (NHL). Modifier of immune response, monoclonal antibodies (MAb) and therapeutics cancer vaccines have shown different grade of outcomes in the management of this heterogeneous disease.

Over the last ten years, the introduction of monoclonal antibodies (MAbs) and specifically the anti-CD20 monoclonal antibody Rituximab has radically changed treatment of B-cell NHL. The use of Rituximab in the treatment of such lymphomas has increased significantly the response rates, the progression free survival and overall survival in both indolent and aggressive B-cell NHL. Based in the results achieved with this drug new strategies of treatment have been developed using MAbs against different epitopes of the CD20 molecule and against other molecules expressed in the surface of lymphoma cell such as CD19, CD22, CD37 and CD30. Moreover, the new drugs such as conjugated antibodies, which are design to carry cytotoxic inside to the target cell; bivalents MAb, and MAb against molecules that regulate the immune response are showing encourages results and they are rapidly moving into efficacy studies. In this review we present the advances in the use of MAb for the treatment of NHL.

Phyllanthus emblica flavonoid glycosides against xanthine oxidase
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1067-1078, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1959_12.6.1067 Original Article Antioxidant potential and xanthine oxidase inhibition of flavonol glycosides from Phyllanthus emblica L. leaves [Potencial antioxidante e inhibición de la xantina oxidasa de los glucósidos de flavonol de las hojas de Phyllanthus emblica L.] Husnunnisa1, Rika Hartati1, Rachmat Mauludin2, … Continue reading Phyllanthus emblica flavonoid glycosides against xanthine oxidase
Spray-drying Perilla frutescens extract optimization
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1056-1066, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2009_12.6.1056 Original Article Optimization of spray-drying conditions and quality assessment of dry extract from Perilla frutescens (L.) Britton leaves [Optimización de las condiciones de secado por atomización y evaluación de la calidad del extracto seco de hojas de Perilla frutescens (L.) Britton] … Continue reading Spray-drying Perilla frutescens extract optimization
Honey clinical applications in complementary medicine
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1040-1055, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1870_12.6.1040 Review Honey clinical applications in complementary medicine: A critical review [Aplicaciones clínicas de la miel en la medicina complementaria: Una revisión crítica] Thai Hau Koo1, Andee Dzulkarnaen Zakaria2*, Mohd Zulkifli Mustafa3 1Department of Internal Medicine, School of Medical Sciences, Universiti Sains … Continue reading Honey clinical applications in complementary medicine

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio